CLSI POCT13
Glucose Monitoring in Settings Without Laboratory Support
CLSI POCT13 Ed3c delivers an easy-to-use question-and-answer format designed to help health care staff monitor patient glucose levels outside hospital laboratories. Whether you're a traveling medical professional or performing community outreach, always have access to these essential FAQs to ensure quality patient care is always delivered.
This edition of the document was corrected in June 2018.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceClinical and Laboratory Standards Institute document POCT13—Glucose Monitoring in Settings Without Laboratory Support was developed for personnel monitoring glucose levels at sites other than a hospital laboratory. In a question and answer format, the document provides recommendations related to administrative structure, operator authorization, test system selection, QA, and test procedure. Samples of a written evaluation and QC logs are also included.
This document replaces the second edition of the guideline, CLSI POCT13-A2, which was published in 2005.
Several changes were made to this edition:
- Safety recommendations in Chapter 2
- Training program recommendations in Subchapter 3.3
- Information related to alternate-site testing in Subchapter 5.3.2
- Information related to glucose meter result variations in Subchapter 5.7.3
This document was corrected in 2018 and replaces the original third edition of the guideline, CLSI POCT13, 3rd ed., which was published in June 2015. Corrections were made as follows:
- In Subchapter 1.4.2, the definition of a lancing device was expanded for clarification.
- In Chapter 2, recommendations regarding the use of lancing devices, lancets, and glucose meters to prevent transmission of blood-borne pathogens were strengthened. Recommendations regarding the use of devices for dispensing insulin were added.
- In Chapter 3, the glucose monitoring program coordinator’s responsibilities for infection control were clarified, including training and oversight practices.
- In Chapter 4, the intended use of blood glucose meters (ie, individual vs multipatient use) was clarified.
- In Chapter 5, the safety recommendations to prevent the transmission of blood-borne pathogens were improved.
This guideline was developed for authorized personnel directly involved in the establishment, management, and implementation of a blood glucose monitoring (BGM) program at sites without support from hospital laboratories.
For the purposes of this document, these authorized personnel are referred to as “operators.” In settings where there is more than one operator, one individual should be designated to coordinate the testing program. For the purposes of this document, this individual is referred to as the “coordinator.” It is assumed that authorized personnel have met the minimum personnel qualifications and training specified by the site coordinator.
This document is available in electronic format only.
This edition of the document has been corrected, read the full correction notice here.
Clinical and Laboratory Standards Institute document POCT13—Glucose Monitoring in Settings Without Laboratory Support was developed for personnel monitoring glucose levels at sites other than a hospital laboratory. In a question and answer format, the document provides recommendations related to administrative structure, operator authorization, test system selection, QA, and test procedure. Samples of a written evaluation and QC logs are also included.
This document replaces the second edition of the guideline, CLSI POCT13-A2, which was published in 2005.
Several changes were made to this edition:
- Safety recommendations in Chapter 2
- Training program recommendations in Subchapter 3.3
- Information related to alternate-site testing in Subchapter 5.3.2
- Information related to glucose meter result variations in Subchapter 5.7.3
This document was corrected in 2018 and replaces the original third edition of the guideline, CLSI POCT13, 3rd ed., which was published in June 2015. Corrections were made as follows:
- In Subchapter 1.4.2, the definition of a lancing device was expanded for clarification.
- In Chapter 2, recommendations regarding the use of lancing devices, lancets, and glucose meters to prevent transmission of blood-borne pathogens were strengthened. Recommendations regarding the use of devices for dispensing insulin were added.
- In Chapter 3, the glucose monitoring program coordinator’s responsibilities for infection control were clarified, including training and oversight practices.
- In Chapter 4, the intended use of blood glucose meters (ie, individual vs multipatient use) was clarified.
- In Chapter 5, the safety recommendations to prevent the transmission of blood-borne pathogens were improved.
This guideline was developed for authorized personnel directly involved in the establishment, management, and implementation of a blood glucose monitoring (BGM) program at sites without support from hospital laboratories.
For the purposes of this document, these authorized personnel are referred to as “operators.” In settings where there is more than one operator, one individual should be designated to coordinate the testing program. For the purposes of this document, this individual is referred to as the “coordinator.” It is assumed that authorized personnel have met the minimum personnel qualifications and training specified by the site coordinator.
This document is available in electronic format only.
This edition of the document has been corrected, read the full correction notice here.